drugset / Trial / NCT03961087

Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy

NCT03961087

Unknown 300 enrolled Zagazig University
RandomizedParallel-groupOpen-labelTreatment

Summary

Hepatic encephalopathy is a syndrome occurs in patients with liver cirrhosis and is defined as neuropsychiatric abnormalities in patients with liver impairment, characterized by personality changes, intellectual impairment, and an impaired level of consciousness. Coenzyme Q10 (CoQ10) is a necessary cofactor of the mitochondrial metabolism. It provides a High antioxidant and protective effects on age-related morbidities such as hypertension, heart failure and neurodegenerative diseases and hepatoprotective effects in drug related hepatic impairment. Meclofenoxate is a cholinergic nootropic drug used clinically to improve memory, mental function and general cognition.

Timeline

Start
2019-05-23
Primary completion
2020-01-01
Completion
2020-02-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Coenzyme Q10 Other / unclassified
Comparator MECLOFENOXATE Small molecule 500 mg